Microbot Medical Inc.
NASDAQ:MBOTMedical - Instruments & Supplies
-$0.06 today
- Market cap
- $65.73M
- Beta
- 1.04
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.21
Volume 0.87M
Average 1.60M
MBOT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Microbot Medical Inc.NASDAQ: MBOT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $3.67M (cash outflow) rose 41.1% year over year, ahead of the +21.8% change in trailing-twelve-month net income. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$13.15M (+0.1%) for the fiscal year ending Dec 2026, a slowdown from the +14.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.67M+6.0% QoQ
- Last fiscal yearDec 2025
- -$13.14M+14.8% YoY
- LTMMar 2026
- -$14.21M+21.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +41.1% | +35.3% | -5.9 pp |
| 1 year | +14.8% | +0.1% | -14.8 pp |
| 3-year CAGR | -0.1% | -10.6% | -10.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (13.14M) USD
- Year-over-year change
- -14.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.14M) | -14.8% |
| FY2024 | 2024-12-31 | (11.44M) | -6.5% |
| FY2023 | 2023-12-31 | (10.74M) | +18.4% |
| FY2022 | 2022-12-31 | (13.17M) | -16.4% |
| FY2021 | 2021-12-31 | (11.31M) | — |
Net Income vs competitors
How MBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +21.8% is the 4th highest of 10, against a peer median of +14.2%.
- Net income amounts to 13535.2% of revenue for MBOT, versus a peer median of 5885.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.7T USD | +200670695.8% | — | 5535061.0% | |
| LTM Mar 2026 | $110M USD | +489.6% | — | — | |
| LTM Mar 2026 | $45.34M USD | -20.5% | +22.1% | 62.7% | |
| LTM Mar 2026 | $40.23M USD | +45.6% | +34.5% | — | |
| LTM Mar 2026 | CA$36.38M CAD | +1.7% | +3.0% | — | |
| LTM Mar 2026 | $33.51M USD | +15.3% | -4.4% | 25009.7% | |
| LTM Mar 2026 | $27.09M USD | +14.1% | +24.2% | — | |
| LTM Mar 2026 | $24.17M USD | -3.2% | -31.5% | 339.3% | |
| LTM Mar 2026 | $14.21M USD | +21.8% | -0.1% | 13535.2% | |
| LTM Mar 2026 | CA$9.78M CAD | +14.2% | -12.1% | 5885.5% | |
| Peer median (excluding MBOT) | — | +14.2% | +3.0% | 5885.5% | |
Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Depreciation & Amortization | 76K | 102K | 106K | 91K | 47K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.39M | 1.75M | 1.39M | 1.35M | 1.06M |
| Change in Working Capital | 497K | (228K) | (11K) | 942K | (1.01M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | (584K) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 497K | (228K) | (11K) | 942K | (424K) |
| Other Non-Cash Items | 1.39M | (7K) | 718K | 234K | 0 |
| Operating Cash Flow | (9.35M) | (11.55M) | (8.53M) | (8.83M) | (13.05M) |
| Capital Expenditures | (69K) | (84K) | (33K) | (25K) | (60K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (3.75M) | (10.06M) | (5.12M) | (82.93M) |
| Sales of Investments | 3.27M | 0 | 12.06M | 6.68M | 10.6M |
| Other Investing Activities | 0 | (3K) | 3K | 0 | 0 |
| Investing Cash Flow | 3.2M | (3.84M) | 1.97M | 1.54M | (72.38M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.15M) | (11.06M) | (2K) | 646K | 810K |
| Free Cash Flow | (9.42M) | (11.63M) | (8.57M) | (8.85M) | (13.11M) |
Microbot Medical Inc.
NASDAQ:MBOT
Intrinsic Alpha fair value
Locked
Current Price
$0.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.